Myleran (1,4-dimethanesulphonyloxybutane) was reported by Haddow and Timmis1 in 1953 to be an active agent against the Walker rat carcinoma 256. Their experimental studies further disclosed that this compound, unlike nitrogen mustard or roentgen rays, induced depression of granulopoiesis without depressing lymphopoiesis. These results stimulated clinical trials by investigators in England2 and the United States3 that subsequently demonstrated that Myleran would produce remissions in patients with chronic granulocytic leukemia. We became interested in this drug not only because the reported results of treatment appeared encouraging but also because its ease of administration on an outpatient basis and its apparent freedom from side-effects offered obvious advantages over x-ray therapy. Our results confirm those already reported.
Methods and Results
Ten patients with chronic granulocytic leukemia were treated with Myleran. Historical data and dosage are summarized in table 1. In all cases the diagnosis was substantiated by clinical examination and
Frost JW, Jackson CB. MYLERAN IN THE TREATMENT OF CHRONIC GRANULOCYTIC LEUKEMIA. JAMA. 1956;161(1):54–56. doi:10.1001/jama.1956.62970010006015b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: